B-Cell NHL

Advertisement
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
Read More
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Mosunetuzumab was safe and efficacious for patients with heavily pretreated relapsed and/or refractory B-cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 9, 2022
Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...
Advertisement
Advertisement
Latest News

April 30, 2025